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PURPOSE. The aim of this study was to determine the role of
gangliosides in pathogenic mechanisms of thyroid-associated
ophthalmopathy (TAO).
METHODS. The gangliosides profile and mRNA level of sialyl-
transferases of the orbital tissues from TAO patients (n  5)
and non-TAO subjects (n  4) were investigated. In addition,
the effect of exogenous gangliosides on the expression of
hyaluronic acid was examined in orbital fibroblasts. For in vitro
experiments, we used four different strains of cells obtained
from non-TAO subjects with at least three replicates for each
strain.
RESULTS. Trisialoganglioside 1b (GT1b) was significantly over-
expressed in the orbital tissue of TAO patients compared with
control tissue, whereas no significant difference was observed
for either monosialoganglioside 1 (GM1) or disialoganglioside
1a (GD1a) by digital analyses of immunohistochemical images.
Moreover, mRNA levels of sialyltransferase (SAT)-I and SAT II
were increased in TAO patients compared with control. Exog-
enous GT1b strongly induced the morphologic changes related
to an accumulation of sparse flocculent precipitates in lyso-
somes and increased the extracellular hyaluronic acid level in
orbital fibroblasts with the induction of hyaluronic acid syn-
thase, which were less by GD1a but not by GM1. The GT1b-
induced morphologic changes of cells were due, at least in
part, to an increase of intracellular hyaluronic acid. Co-treat-
ment of hyaluronidase nicely attenuated the morphologic
changes in orbital fibroblasts. Thy-1 orbital fibroblasts were
more capable of producing hyaluronic acid by exogenous
GT1b.
CONCLUSIONS. The results suggest that gangliosides, particularly
GT1b, may play a role in the pathologic mechanisms of TAO by
stimulating an increase in hyaluronic acid. (Invest Ophthalmol
Vis Sci. 2011;52:264–273) DOI:10.1167/iovs.10-5276
Graves’ disease is a common autoimmune disorder of thethyroid in which stimulatory antibodies bind to the thy-
rotropin receptor and activate glandular functions, resulting in
hyperthyroidism.1 Approximately 25% to 50% of patients with
Graves’ disease develop involvement of the orbit, and approx-
imately 5% of patients suffer from severe ophthalmopathy,
including intense pain, chemosis, proptosis, lid retraction, dou-
ble vision, or even loss of vision.2 The pathogenesis of thyroid-
associated ophthalmopathy/orbitopathy (TAO) is not com-
pletely understood, but it is widely accepted that TAO is
induced by the autoimmune response and not by the metabolic
perturbations associated with thyroid hormone overproduc-
tion.3,4 Most of the clinical manifestations of TAO can be
explained by the discrepancy between the increased volume of
orbital tissues and the fixed volume of the bony orbit.5 This
volumetric increase of orbital tissues is mainly due to swelling
and is characterized by edematous changes of orbital fatty
connective tissue6 and extraocular muscles without muscle
cell pathology.7
The hallmark feature of the connective tissue remodeling
encountered in TAO is the accumulation of hyaluronic acid in
retroocular tissue.8 Hyaluronic acid is a high-molecular-weight
glycosaminoglycan composed of D-glucuronic acid and N-
acetyl-D-glucosamine residues. Because of its profound hydro-
philic nature and extreme molecular bulk when hydrated, the
accumulation of hyaluronic acid accounts, at least in part, for
the expansion of orbital tissues and the expansion of the eye
beyond the normal boundaries of the bony orbit.5 Orbital
fibroblasts, which are abundant in orbital connective tissue and
the orbital fatty compartment, are an important source of
hyaluronic acid.8 A variety of inflammatory mediators, includ-
ing interleukin (IL)-1ß and transforming growth factor (TGF)-,
have been shown to stimulate hyaluronic acid synthesis in
cultured human orbital fibroblasts.9,10
Gangliosides are sialic acid (NeuAc)-containing glycosphin-
golipids that have a variable sialic acid–containing oligosaccha-
ride structure attached to an acylated ceramide core.11 During
ganglioside synthesis, sialyltransferases catalyze the transfer of
sialic acid from cytidine monophosphosialic acid–sialic acid to
the terminal position of sugar chains of glycolipids12,13; gan-
glioside subtypes are defined by the number and site of sialic
acids. Gangliosides are widely distributed in the plasma mem-
branes of all vertebrate tissue14 and are important in cell
differentiation,15 proliferation,16 and signal transduction.17 In
the thyroid, gangliosides are a structurally and functionally
important element of the thyrotropin receptor and affect thy-
rotropin binding and thyrocyte function.18–22 Interestingly,
sialyltransferase activity is increased in the thyroid tissue of
patients with Graves’ disease.23
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In this study, we found an increased expression of trisialo-
ganglioside 1b (GT1b) and an enhanced mRNA level of both
sialyltransferase (SAT)-I and SAT II in orbital tissues of patients
with TAO. Orbital fibroblasts from non-TAO subjects exhibited
morphologic changes on exogenous treatment with GT1b,
whereas dermal fibroblasts and preadipocytes were irrespon-
sive to it. These morphologic changes were associated with an
increase in intracellular hyaluronic acid; the level of extracel-
lular hyaluronic acid also increased in GT1b-treated orbital
fibroblasts. Co-treatment of Streptomyces hyaluronidase with
GT1b reduced the extracellular hyaluronic acid level as well as
the intracellular one accompanying with the attenuation of the
morphologic changes in cells. Our results demonstrate that
change in gangliosides profiling modulate the pathogenic
mechanism of TAO by stimulating an increase in hyaluronic
acid.
MATERIALS AND METHODS
Reagents
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum
(FBS), penicillin, streptomycin, and trypsin/ethylenediaminetetraacetic
acid (EDTA) were purchased from HyClone (Logan, UT). Bovine serum
albumin (BSA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT), and Streptomyces hyalurolyticus hyaluronidase were
obtained from Sigma-Aldrich (St. Louis, MO). Goat serum was obtained
from Vector Laboratories (Burlingame, CA). Bovine brain monosialo-
ganglioside 1 (GM1), disialoganglioside 1a (GD1a), and trisialoganglio-
side 1b (GT1b) were purchased from Matreya (Pleasant Gap, PA).
Mouse anti-GM1 Ab (clone GMB16), mouse anti-GD1a Ab (clone
GMR17), and mouse anti-GT1b Ab (clone GMR5) were purchased from
Seikagaku Corporation (Tokyo, Japan). Sheep polyclonal anti-hyalu-
ronic acid Ab, rabbit polyclonal anti-lysosome-associated membrane
glycoprotein (LAMP)-2b Ab, mouse monoclonal anti-Thy-1 Ab, PE-
conjugated donkey polyclonal anti-sheep Ab, and biotin-conjugated
anti-mouse Ab were obtained from Abcam (Cambridge, UK). FITC-
conjugated anti-mouse Ab, Alexa Fluor 350–conjugated anti-sheep Ab,
and Alexa Fluor 555–conjugated anti-rabbit Ab were purchased from
Molecular Probes (Eugene, OR). Streptavidin complexed with biotin-
ylated horseradish peroxidase and 3,3-diaminobenzinidine (DAB)
were obtained from Dako Cytomation (Carpinteria, CA). A hyaluronic
acid-ELISA kit was obtained from Echelon Biosciences (Salt Lake City,
UT). Guanidinium thiocyanate-phenol-chloroform medium was pur-
chased from Invitrogen (TRIzol; Carlsbad, CA), and random hexamer
was purchased from Amersham Pharmacia Biotech (Uppsala, Sweden).
dNTP was obtained from Boehringer-Mannheim (Mannheim, Ger-
many), and reverse transcriptase was purchased from GIBCO (Invitro-
gen, Carlsbad, CA). Taq polymerase and thermal cycler were pur-
chased from Perkin Elmer (Norwalk, CA).
Orbital Tissue Collection and Cell Culture
Orbital fatty connective tissues were obtained as surgical waste during
decompression surgery for patients with TAO (n  5) and during
orbital surgery for subjects without Graves’ disease or other inflamma-
tory disease (n 4). Orbital fibroblasts were cultivated from the orbital
tissues, and four individual cell strains of the non-TAO subjects were
used for in vitro experiments. Before the decompression surgery, all
TAO patients had experienced at least 6 months of inactive disease
status within euthyroid condition. Patient characteristics are presented
in Table 1. Dermal fibroblasts were cultivated from eyelid skin of
subjects undergoing cosmetic lid surgery (n 3). These activities were
undertaken after informed consent was obtained from the donors
according to procedures approved by the Institutional Review Board of
Ajou University Hospital and following the tenets of the Declaration of
Helsinki. Mouse preadipocyte cell line 3T3-L1 (ATCC CCL 92.1) was
purchased from the American tissue culture collection (Manassas, VA).
Cell cultures were maintained in a humidified 5% CO2 incubator at
37°C covered with DMEM containing 10% FBS and antibiotics (DMEM
10% FBS). Once a fibroblasts monolayer was obtained, cultures were
serially passaged after gentle treatment using trypsin/EDTA. Liquid
nitrogen was used in the long-term storage of some cultures. Medium
was changed every 3 days, and cells beyond passage 6 from culture
initiation were not used.
Immunohistochemistry and Measurement of
Immunoreactive Areas
Orbital tissue cryostat sections (10 m) were prepared and fixed with
acetone at room temperature for 5 minutes followed by complete air
drying. Slides were kept at room temperature and incubated for 15
minutes in phosphate-buffered saline (PBS) for rehydration and 30
minutes in blocking solution containing 10% goat serum in PBS, fol-
lowed by several washes in PBS. The sections were treated for 30
minutes with one of the following primary antibodies: anti-GM1 Ab
(1:1000), anti-GD1a Ab (1:1000), or anti-GT1b Ab (1:1000), washed
repeatedly in PBS, and incubated for 30 minutes with biotin-conjugated
secondary Ab. After washing in PBS, endogenous peroxidase was
blocked with 0.3% H2O2 diluted in methanol for 15 minutes, and
streptavidin complexed with biotinylated horseradish peroxidase was
applied for 20 minutes Each slide was washed in PBS and incubated
with DAB for 15 minutes; the chromogenic reaction was terminated by
washing in PBS. Microscopic examinations were performed using the
BX51 (Olympus Optical, Tokyo, Japan) at 100, 200, and 400
magnification. To analyze the amount of ganglioside staining, three
nonperipheral, noncontinuous, random fields of view at 100, se-
lected by one observer who had no access to the clinical details of the
specimens, were exported from each slide using a microscope-
mounted digital camera under the same condition of lighting through-
out the experiment. Using ImageJ software (developed by Wayne
Rasband, National Institutes of Health, Bethesda, MD; available at
http://rsb.info.nih.gov/ij/index.html), each image was converted to
8-bit gray scale, and area densities were measured from the pixels in
the region of interest. To exclude background error, only pixels ex-
ceeding an intensity value 50, based on the negative value measured
from the images of specimen stained without primary antibody, were
included.
Reverse Transcriptase–Polymerase Chain
Reaction (RT-PCR) Analysis
Total RNA was prepared from orbital fat tissue using TriZol. cDNA
was synthesized from 5 g of total RNA using 1 L of random
hexamer (2 g/L), 1.25 mM dNTP, and 200 U M-MLV reverse
transcriptase. PCR was performed using 3 L cDNA, 0.25 mM dNTP,
TABLE 1. Characteristics of TAO Patients and Non-TAO Subjects from
Whom Orbital Tissues Were Obtained
Patients with
TAO (n  5)
Non-TAO
Subjects (n  4)
Mean age, y (range) 40 (29–57) 43 (32–54)
Sex (male/female) 3/2 2/2
Smoking (yes) 0 0
Graves’ disease 5 0
Radioactive iodine therapy 0 —
Surgery 0 —
Methimazole 5 —
Treatment TAO 5 0
Surgery 5 —
Prednisone 3 —
Radiation 0 —
Euthyroid 5 4
TSH-receptor antibodies 5 0
Clinical activity score
(range)
1 (0–2) —
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0.25 U of Taq polymerase, and 10 pmole of primer pair with a
thermal cycler. PCR cycling conditions were as follows: 92°C for 30
seconds, 55°C for 30 seconds, and 72°C for 1 minute. Primer
sequences are listed in Table 2.
Morphologic Analysis of Cells
For experiments, cells were inoculated in 35 mm cell culture dishes
covered with DMEM 10% FBS and allowed to attach and spread for 3
days. Then the cells were incubated overnight in DMEM supplemented
with 1% charcoal-filtered FBS and antibiotics (DMEM 1% FBS). Subse-
quently, cells were washed and cultured in DMEM 1% FBS with or
without each type of gangliosides; GM1, GD1a, and GT1b. After 48
hours of treatment, cells were fixed with 10% formalin in PBS and
washed three times with PBS. Cell morphology was examined by
inverted microscope (Axiovert 200M, Carl Zeiss, Baden-Wu¨rttemberg,
Germany). To analyze the number of cells that underwent the mor-
phologic changes, three nonperipheral, noncontinuous, random fields
of view at 100, selected by one observer who had no access to the
clinical details of the specimens were exported from each slide using
a microscope-mounted digital camera under the same lighting condi-
tions throughout the experiment. Then the cells were counted manu-
ally from the obtained images. For transmission electron microscopic
analyses, cells were fixed with Karnovsky’s fixative solution (2% para-
formaldehyde, 2% glutaraldehyde, 0.5% calcium chloride in cacodylate
buffer, pH 7.2) for 30 minutes, washed with cacodylate buffer, dehy-
drated with a graded ethanol series, and embedded in epon. Ultrathin
sections (75 nm) were obtained using a microtome (Reichert Jung
Ultracut S; Leica, Vienna, Austria). Sections were mounted on grids,
stained with uranyl acetate and lead citrate, and observed under an
electron microscope (EM 902A; Carl Zeiss).
Cytotoxicity Assay
Cell growth and death were assessed using MTT assays. Orbital fibro-
blasts (1  105) were seeded into 24-well culture plates and incubated
in DMEM 1% FBS with (4 or 40 g/mL) or without GT1b for 48 hours.
After washing cells with PBS, 50 L of MTT solution (1 mg/mL in PBS)
was added to each well, and plates were incubated for 4 hours at 37°C.
The plates were centrifuged at 3000g for 10 minutes, and supernatant
was carefully removed. The remaining adherent cells were then dis-
solved in 200 L dimethyl sulfoxide (DMSO), and optical density was
measured at 570 nm using a microplate reader.
Alcian Blue Staining
Orbital fibroblasts cultured on poly-D-lysine-coated slide were treated
with GT1b in DMEM 1% FBS for 48 hours. Cells were then washed
twice with PBS and fixed in 4% paraformaldehyde for 20 minutes. After
three washings with PBS, cells were stained with alcian blue solution
(1% w/v alcian blue in 3% acetic acid, pH 2.5) for 30 minutes. After four
washings with distilled water and dehydration with 95% ethanol, the
slide was mounted and examined.
Quantitative Assay of Hyaluronic Acid by ELISA
Orbital fibroblasts were plated in 6-well plastic culture plates and
incubated for the indicated time periods with or without gangliosides
(GM1, GD1a, or GT1b), in DMEM 1% FBS. Supernatants from the cell
cultures were collected, and hyaluronic acid concentrations were
determined using a competitive binding hyaluronic acid-ELISA kit ac-
cording to the manufacturer’s instructions. Briefly, after adding of 100
L of standards and samples into corresponding wells, 150 and 100 L
of diluents were added to blank and zero hyaluronic acid control wells,
respectively. Fifty microliters of working detector was added to all
wells except the blank and mixing, and the plate was covered and
incubated for 1 hour at 37°C. Then 100 L of controls and samples
were transferred to the corresponding wells of the hyaluronic acid-
ELISA plate. After incubation for 30 minutes at 4°C, the solution was
discarded, and the wells were washed and 100 L of working enzyme
suspension was added to each well. After incubation for 30 minutes at
37°C and washing, 100 L of working substrate solution was added to
each well, and the plate was incubated in the dark at room temperature
for 30 minutes. Finally, absorbance was spectrophotometrically mea-
sured at 570 nm. The concentration of hyaluronic acid in the sample
was determined using a standard curve generated with known
amounts of hyaluronic acid.
Immunofluorescence Assay
Orbital fibroblasts cultured on poly-D-lysine-coated slide were treated
with GT1b in DMEM 1% FBS for 48 hours. After washing with PBS and
fixing with 4% paraformaldehyde, the cells were then washed in PBS
and incubated for 10 minutes at room temperature with permeabiliza-
tion buffer (PBS containing 0.1% Triton X-100). After washing several
times with PBS, the cells were blocked with 5% BSA in PBS for 30
minutes at room temperature and then incubated overnight at 4°C
with the following primary antibodies: anti-GT1b Ab (1:1000), anti-
hyaluronic acid Ab (1:1000), and anti-LAMP2b Ab (1:1000). Cells were
washed three times and incubated for 2 hours at room temperature
with the following secondary antibodies: FITC-conjugated anti-mouse
Ab, Alexa Fluor 350–conjugated anti-sheep Ab, and Alexa Fluor 555–
conjugated anti-rabbit Ab. To examine the relevance of Thy-1 expres-
sion with the GT1b-induced hyaluronic acid increase in orbital fibro-
blasts, anti-Thy-1 Ab (1:1000) and anti-hyaluronic acid Ab (1:1000)
were used for primary Ab, followed by the use of PE-conjugated
anti-sheep Ab for the secondary one. After mounting, the cells were
observed under a confocal microscope (Carl Zeiss).
Statistical Analysis
Student’s t-tests were used in analyzing the difference expression of
gangliosides and SAT in orbital tissues of patients with TAO and normal
subjects. The effect of gangliosides on the hyaluronic acid increase and
the attenuative effect of hyaluronidase on the ganglioside-induced
morphologic changes were analyzed using the same tests. Statistical
software (SPSS 15.0; SPSS Inc., Chicago, IL) was used for analysis, and
P  0.05 was considered statistically significant.
TABLE 2. Sequences of Primers Used for RT-PCR
Genes Sense 5-3 Antisense 5-3
SAT I GACCCTCTTGGAACTCTTGCC CCAAACTGACTTCATCGCACA
SAT II ATCCCAGCATAATTCGGC AGAAGGGCCAGAAGCCAT
SAT IV GGACCCTGAAAGTGCTCA TCTCCAGCATAGGGTCCA
HAS1 TGTGTATCCTGCATCAGCGGT CTGGAGGTGTACTTGGTAGCATAACC
HAS2 GTGTTATACATGTCGAGTTTACTTCC GTCATATTGTTGTCCCTTCTTCCGC
HAS3 GGTACCATCAGAAGTTCCTAGGCAGC GAGGAGAATGTTCCAGATGCG
Actin GCCATCTCCTGCTCGAAGTCTAG CATGTTTGAGACCTTCAACACCCC
HAS, hyaluronic acid synthase; SAT I, -galactoside -2,3-sialyltransferase 5; SAT II, -galactoside
-2,8-sialyltransferase 1; SAT IV, -galactoside -2,3-sialyltransferase 1.
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RESULTS
GT1b Overexpressed in Orbital Tissues of
TAO Patients
To determine whether gangliosides are associated with the
pathogenesis of TAO, we examined the level of gangliosides in
orbital tissue by immunohistochemical staining. Orbital fat
tissues were obtained during orbital decompression surgery of
TAO patients (n  5) and during orbital surgery of subjects
without Graves’ disease or other inflammatory diseases as a
control (n  4). Monoclonal antibodies specific for each gan-
glioside subtype (GM1, GD1a, and GT1b) were used for stain-
ing. As shown in Figure 1A, GM1 and GD1a were abundantly
expressed in TAO and control tissues. The mean GM1-stained
area (%) in TAO sections was 7.8  2.9 and in control sections
was 6.6  0.2, showing no statistical difference (P  0.507).
The area stained for GD1a was 1.7  1.2 in control sections
and 2.7  1.4 in sections from TAO patients, with no signifi-
cant difference (P  0.320). However, GT1b expressed cells
were found only in TAO, not in control tissues. GT1b expres-
sion was significantly increased in orbital tissues of TAO pa-
tients compared with control tissues (3.6  1.4% and 0.03 
0.06%, respectively; P  0.004; Fig. 1B).
Increased mRNA Level of Sialyltransferases in
Orbital Tissues from Patients with TAO
Cellular ganglioside composition relies on the balance between
the activities of several sialyltransferases acting at the branch-
ing points of ganglioside biosynthesis.24 RT-PCR analysis of
orbital fatty connective tissue was used to detect the mRNA
level of: sialyltransferase I (SAT I, ST3 -galactoside -2,3-
sialyltransferase 5), which converts lactosylceramide to the
a-series monosialoganglioside GM3; sialyltransferase II (SAT II,
ST8 -N-acetyl-neuraminide -2,8-sialyltransferase 1), which
converts GM3 to b-series disialoganglioside GD3; and sialyl-
transferase IV (SAT IV, ST3 -galactoside -2,3-sialyltransferase
1), which converts GM1 to GD1a (a-series) and GD1b to GT1b
(b-series). As shown in Figure 2, the mRNA levels of SAT I and
SAT II were significantly increased in TAO tissue compared
with control tissue (P  0.001  0.049, respectively), corre-
sponding to the increased expression of GT1b shown in Fig 1.
Although the difference was not statistically significant, the
mRNA level of SAT IV in the patient group was slightly higher
than the control (P  0.160). These results suggest that in-
creased expression of GT1b in the orbital tissue of TAO pa-
tients may be due to the enhanced activities of sialyltrans-
ferases.
Effect of Gangliosides GM1, GD1a, and GT1b on
Orbital Fibroblast Morphology
Exogenous gangliosides interact with plasma membranes and
modulate transmembrane signaling pathways.16 Because the
orbital tissues of TAO patients showed increased expression of
GT1b and sialyltransferase, we tested the impact of added
gangliosides on orbital fibroblasts. The three types of ganglio-
sides (GM1, GD1a, GT1b; 40 g/mL each) were applied indi-
vidually to the orbital fibroblasts obtained from non-TAO sub-
jects (n 4), dermal fibroblasts (n 3), and preadipocytes. As
shown in Figure 3A, GM1 induced no noticeable morphologic
changes in orbital fibroblasts at 48 hours compared with con-
trol, whereas GD1a yielded a few cells with morphologic
changes including more rounding and brightening of cells. The
morphologic changes were most prominent in GT1b-treated
cells. None of the gangliosides induced morphologic changes
of the dermal fibroblasts or preadipocytes up to 48 hours,
indicating that the effect of GT1b on orbital fibroblasts is cell
FIGURE 1. Increased GT1b expres-
sion in orbital tissues of TAO patients.
(A) Orbital fatty connective tissues
were obtained during decompression
surgery of patients with TAO (n  5),
and from non-TAO subjects who un-
derwent orbital surgery for noninflam-
matory reasons as control (n  4).
Cryosections (10 m) were stained for
GM1, GD1a, and GT1b, respectively.
Representative experiment showing
increased GT1b expression in orbital
tissue of TAO patient compared with
control. Scale bars, 200 m; negative
control, no primary Ab. (B) Quantita-
tive analysis of immunoreactivity. Pos-
itively stained areas were measured us-
ing Image J software program (bar
graph, mean  SD).
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specific. Ultra-structural studies showed that GT1b-treated or-
bital fibroblasts were filled with numerous single membrane-
bound bodies containing flocculent, medium-dense materials
and particulate precipitates (Fig. 3B). To clarify whether these
morphologic changes of orbital fibroblasts by GT1b were re-
sulted from its impact on the cell viability, MTT assays were
performed with the range of dose used in this study. As shown
in Figure 3C, the viability of orbital fibroblasts from non-TAO
subjects was not affected by the incubation of GT1b at con-
centrations of up to 40 g/mL for 48 hours.
Increase of Hyaluronic Acid in Orbital Fibroblasts
by GT1b
TAO is associated with an accumulation of hyaluronic acid in
the extracellular space of orbital connective tissue,8 and orbital
fibroblasts are believed to be the source of hyaluronic acid.
Interestingly, the electromicroscopic findings observed in Fig-
ure 3B are similar to the ones of histiocytes from a patient with
a lysosomal storage disease, which is caused by a genetic
deficiency of hyaluronidase resulting in the intracellular accu-
mulation of hyaluronic acid.25 To determine whether the in-
travesicular precipitate observed in GT1b-treated orbital fibro-
blasts was hyaluronic acid, we performed IFA of GT1b-treated
orbital fibroblasts using antibodies for hyaluronic acid as well
as the lysosomal marker LAMP2b. Compared with untreated
control, GT1b-treated cells had numerous deposits of hyal-
uronic acid, especially along cellular membranes, and some of
the deposited hyaluronic acid was co-localized with lysosomes
(Fig. 4A). Moreover, corresponding to the differential effect of
gangliosides on the morphologic changes in orbital fibroblasts
shown in Figure 3A, GT1b-treated cells were most strongly
stained by alcian blue, indicating the intracellular increase of
hyaluronic acid (Fig. 4B). In addition, the extracellular concen-
trations of hyaluronic acid were measured after treatment with
each subtype of gangliosides: GM1, GD1a, or GT1b, using
competitive ELISA. Orbital fibroblasts were treated with 40
g/mL of each ganglioside, and the concentration of hyal-
uronic acid in supernatant was measured at various time points
up to 48 hours. As the data in Figure 4C demonstrate, the level
of hyaluronic acid increased threefold after 48 hours of treat-
ment with GT1b compared with control cells (197.8 ng/105
cells and 61.0 ng/105 cells, respectively). GD1a induced the
increase of hyaluronic acid level at 24 hours after treatment
(68.2 ng/105 cells; 28.4 ng/105 cells in untreated control), but
the level fell into the insignificant range at 48 hours (83.9
ng/105 cells). GM1 showed no significant effect on the increase
of hyaluronic acid in orbital fibroblasts throughout the ob-
served periods. RT-PCR analysis was performed to examine the
effect of GT1b on hyaluronic acid synthase (HAS) expression.
As shown in Figure 4D, mRNA levels of three isoforms of HAS
(HAS1, 2, and 3) were increased by GT1b treatment at 12 and
24 hours. Collectively, our results indicate that exogenous
GT1b treatment increases both extracellular and intracellular
levels of hyaluronic acid in orbital fibroblasts with the induc-
tion of synthesis.
Attenuation of GT1b-Induced Morphologic
Changes in Orbital Fibroblasts by Hyaluronidase
To examine the relevance of GT1b-induced morphologic
changes with the increase of hyaluronic acid in orbital fibro-
blasts, 5 units/mL of Streptomyces hyaluronidase was added
with GT1b (40 g/mL). After 48 hours of incubation, cells that
underwent morphologic changes were counted. The level of
hyaluronic acid in the culture media was reduced after co-
treatment of orbital fibroblasts with hyaluronidase and GT1b
(data not shown). As shown in Figure 5A, the GT1b-induced
morphologic changes of cells were attenuated by co-treatment
with hyaluronidase. And correspondingly, cells co-treated with
hyaluronidase stained for alcian blue with decreased intensity
compared with the ones treated with GT1b only. The percent-
age of morphologically changed cells those were co-treated
with GT1b and hyaluronidase was significantly less than that of
cells treated with GT1b alone (10.3  2.6% and 41.1  7.9%,
respectively; P  0.001; Fig. 5B). Hyaluronidase alone had no
detectable effect on cellular morphology. Taken together, our
data suggest that GT1b causes morphologic changes of orbital
fibroblasts by increasing hyaluronic acid, and hyaluronidase
can attenuate this effect.
Different Capability of Orbital Fibroblasts to
Increase Hyaluronic Acid by GT1b Depending on
Thy-1 Expression
Orbital fibroblasts are believed to make up two populations
according to the expression of Thy-1.26 Interestingly, these
cells in each subpopulation exhibit distinct phenotypes.27 To
investigate whether Thy-1 and/or Thy-1 fibroblasts were
capable of increasing hyaluronic acid by GT1b treatment, we
performed IFA of GT1b-treated orbital fibroblasts using anti-
bodies for Thy-1 and hyaluronic acid. As shown in Figure 6,
cells showing the increase in staining for hyaluronic acid by
GT1b were also stained strongly for Thy-1 (left lower inset),
but Thy-1 cells were not stained for hyaluronic acid (right
upper inset).
DISCUSSION
Our results demonstrate for the first time the increased expres-
sion of GT1b in orbital tissues from TAO patients. Exogenous
GT1b strongly induced the morphologic change and the in-
crease of hyaluronic acid in orbital fibroblasts from non-TAO
subjects, which were less by GD1a and not by GM1. The effect
of GT1b was shown specifically in orbital fibroblasts, but not in
dermal fibroblasts or preadipocytes. The appearance of new
gangliosides and changes in the cellular ganglioside profile are
FIGURE 2. Enhanced mRNA expression of sialyltransferases in orbital
tissues of TAO patients. (A) RT-PCR analysis of three subtypes of
sialyltransferases (SAT I, SAT II, and SAT IV) in orbital tissues obtained
from TAO patients (n  5) and from control subjects (n  4). Five
micrograms of total RNA was used from each orbital tissue, and RT-PCR
was performed. The experiment shown is representative of the three
studies performed. (B) Relative signal intensities of sialyltransferases.
Densiometric measurements were performed with the bands from (A).
The measured intensities of sialyltransferases were corrected by the
level of actin in each lane and analyzed (bar graph, mean  SD).
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important aspects of cellular metabolism,28–30 and several sia-
lyltransferases catalyze the conversion of one ganglioside to
another.31 In certain pathologic states, the upregulation of one
sialyltransferase results in the overproduction of a particular
ganglioside and an increase in the overall ganglioside concen-
tration.32 Kiljanski et al. found that mRNA levels of SAT I and
SAT IV were significantly increased in thyroid tissues from
patients with Graves’ disease.23 Here we show that mRNA
levels of SAT I, which catalyzes the conversion of lactoceram-
ide into GM3 (an a-series monosialoganglioside), and SAT II,
which catalyzes the conversion of GM3 into GD3 (a b-series
substrate for GT1b), were significantly increased in the orbital
tissues of TAO patients, suggesting that the increased expres-
sion of GT1b in TAO orbital tissue was resulted from the
increased activities of these enzymes. Increased GT1b expres-
sion could be either a cause or an effect of TAO. In our system,
exogenous GT1b induced morphologic changes and overpro-
duction of hyaluronic acid in orbital fibroblasts obtained from
non-TAO patients. Therefore, we may propose that the in-
creased expression of GT1b and the enhanced activity of sia-
lyltransferases in the orbital tissues of TAO patients are in-
volved in the cause of disease pathogenesis.
From the insight of a changed ganglioside profile in certain
pathologic states, several studies have been conducted to elu-
cidate the differential effect of gangliosides depending on their
subtypes. In our study the morphologic changes and the in-
crease of hyaluronic acid in orbital fibroblasts were most strik-
ingly induced by GT1b, less by GD1a, and not by GM1. Similar
to our observations, gangliosides have relative potency in in-
hibition of the binding of fibroblast growth factor (FGF)-2 to
FGF receptors in transformed fetal bovine aortic endothelial
cells (GM7373); GT1b GD1b GM1.33 However, the reason
for the differential effect of gangliosides by their subtypes is
not fully understood. The oligosaccharide chain of gangliosides
contains a variable number of sialic acid (N-acetyl-neuraminic
acid, NeuAc) residues. Compared with GM1 and GD1a, which
are in the a-series characterized by the linkage of one sialic acid
to the nonreducing end of the galactose part, GT1b belongs to
the b-series, which contains the structure NeuAc(238)NeuAc
attached to the internal galactose.34 Moreover, GT1b has three
sialic acids: two linked to the nonreducing end of the galactose
part and one terminal sialic acid residue (two in GD1a and one
in GM1).34 Thus, it may be speculated that this structural
difference of gangliosides played a role in their ability to induce
the morphologic changes and increase hyaluronic acid in or-
bital fibroblasts.
Hyaluronic acid, a high-molecular-weight glycosaminogly-
can, is believed to be an important mediator of TAO because of
its profound hydrophilic nature and its extreme molecular bulk
when hydrated. Orbital fibroblasts synthesize a high level of
FIGURE 3. Effect of gangliosides
GM1, GD1a, and GT1b on orbital fibro-
blast morphology and released hyal-
uronic acid level. (A) Orbital fibro-
blasts, dermal fibroblasts, both from
non-TAO subjects (n  4), and preadi-
pocytes (3T3–L1) were treated with
40 g/mL each of GM1, GD1a, and
GT1b. After 48 hours of treatment, cel-
lular morphology was examined by in-
verted microscope. Representative
data from three replicates for each
strain is shown. Scale bars, 100 m.
(B) Electron microscopic findings of
GT1b-treated orbital fibroblasts. Or-
bital fibroblasts of non-TAO subjects
were treated with 40 g/mL of GT1b.
After 48 hours of treatment, cells were
fixed and examined by transmission
electron microscope. Compared with
untreated control (left), numerous
membrane-bound granules containing
a medium-dense, flocculent material
were noted (asterisk) in the cytoplasm
of GT1b-treated cell (right). Represen-
tative data of three replicates is shown.
Scale bars, 2.5 m. (C) Effect of GT1b
on the viability of orbital fibroblasts.
Orbital fibroblasts from the non-TAO
subjects were seeded into 24-well cul-
ture plates and treated with (4 or 40
g/mL) or without GT1b for 48 hours.
After treatment, cells were washed
and incubated with 50 L MTT solu-
tion (1 mg/mL) for 4 hours at 37°C.
Cells were then dissolved in DMSO
and analyzed spectrophotometrically.
Results are expressed as means  SDs
in relative optical density units (com-
pared with untreated control); normal-
ized values are shown. Assays were
performed at least three times in qua-
druplicate; the data from a representa-
tive experiment are shown.
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FIGURE 4. Induction of hyaluronic acid synthesis by GT1b in orbital fibroblasts. (A) Orbital fibroblasts obtained from non-TAO subjects
(n  4) were treated with 40 g/mL of GT1b for 48 hours. After fixing, immunofluorescence staining was performed with primary antibodies
for anti-hyaluronic acid (green), anti-LAMP2b (red), and anti-GT1b (blue); multiple spotty depositions of hyaluronic acid in cell cytoplasm,
especially along the cell membrane (arrowheads), which partly co-localized with lysosomes (arrow). Representative example of immuno-
fluorescence staining examined by confocal microscope from three independent experiments. Scale bars, 10 m. Negative control, no
primary Ab. (B) Alcian blue–stained images of gangliosides-treated orbital fibroblasts. Orbital fibroblasts from the non-TAO subjects were
treated with 40 g/mL of each ganglioside: GM1, GD1a, and GT1b, and cells were stained with alcian blue (pH 2.5). Light blue stain indicates
hyaluronic acid. Representative from three independent experiments. Scale bars, 100 m. (C) Concentration of released hyaluronic acid in
ganglisosides-treated orbital fibroblasts measured by ELISA. Orbital fibroblasts from non-TAO subjects were treated as described in (B).
Culture media was collected at each indicated time point and subjected to analysis with a specific ELISA for hyaluronic acid. Adherent cells
were trypsinized and counted for standarization. Graph shows mean  SD of three independent replicates (*P  0.05). (D) RT-PCR analysis
of HAS1, HAS2, and HAS3 mRNA levels in GT1b-treated orbital fibroblasts of non-TAO subjects. Cultures were treated with GT1b (40 g/mL)
for 12 or 24 hours. RNA was extracted and subjected to RT-PCR using isoform-specific primers. The experiment shown is representative of
three independent studies performed.
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hyaluronic acid, and the accumulation of hyaluronic acid leads
to the expansion of orbital tissues, resulting in the expansion
of the eye beyond the normal boundaries of the bony orbit.5
Hyaluronic acid is synthesized by a class of integral membrane
proteins called hyaluronic acid synthase (HAS), of which ver-
tebrates have three types (HAS1, HAS2, and HAS3), and ex-
truded through the plasma membrane into the extracellular
matrix or onto the cell surface.35 Inflammatory mediators such
as IL-1ß and TGF-, which are highly expressed in the orbital
tissues of TAO patients, have been reported to increase hyal-
uronic acid synthesis in cultured human orbital fibroblasts by
the induction of HAS.10,36 In our study, GT1b increased mRNA
FIGURE 5. The attenuation of the
GT1b-induced morphologic changes
and increase of hyaluronic acid by hy-
aluronidase in orbital fibroblasts. (A)
Cultivated orbital fibroblsts from non-
TAO subjects (n  4) were treated
with 40 g/mL of GT1b and with or
without 5 units/mL of Streptomyces
hyaluronidase. After 48 hours of incu-
bation, cells were examined by in-
verted microscope (upper) or by al-
cian blue staining (pH 2.5) (lower).
Light blue stain indicates hyaluronic
acid. Representative from three inde-
pendent experiments. Scale bars, 100
m. (B) Number of cells showing the
morphologic changes in (A) was
counted and presented as a percent-
age of the total counted cells (bar
graph, mean  SD).
FIGURE 6. Different capability of orbital fibroblasts to increase hyaluronic acid by GT1b depending on Thy-1 expression. Orbital fibroblasts from
non-TAO subjects (n  4) were treated with 40 g/mL of GT1b for 48 hours. After fixing, immunofluorescence staining was performed with primary
antibodies for Thy-1 (green) and hyaluronic acid (red), and DAPI (4,6-diamidino-2-phenylindole) was used for nuclear stain (blue); positively stained cells
for hyaluronic acid and Thy-1 (left lower insets), and double negative cells (right upper insets). Representative example of immunofluorescence staining
examined by confocal microscope from three independent experiments. Scale bars: 50 m; 10 m in insets.
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levels of these enzymes, suggesting that GT1b induced the
synthesis of hyaluronic acid in orbital fibroblasts. Interestingly,
a potential role of GT1b in modulating the immunologic pro-
cess has been suggested. GT1b suppresses the immunoglobu-
lin production in human peripheral blood mononuclear cells
without affecting the proliferation or viability of cells.37 GD1b,
GT1b, and GQ1b, the b-series of gangliosides, enhance IL-2 and
IFN- production in phytohemagglutinin-stimulated human T
cells, whereas GM1, GM2, GM3, GD1a, GD2, and GD3 do not
alter the secretion of these cytokines.38 Thus, it could be
suggested that GT1b is one of the potent enhancers of HAS
expression in orbital fibroblasts, as well as the inflammatory
mediators such as IL-1ß and TGF-.
Here we have shown that GT1b induces the dramatic en-
hancement of intracellular hyaluronic acid as well as extracel-
lular ones in orbital fibroblasts. The increase of extracellular
hyaluronic acid was initiated 6 hours after GT1b treatment, but
the morphologic changes were not noticeable until at least 24
hours after treatment (Y-HC and KHK, unpublished observa-
tion, 2009), indicating that the morphologic changes followed
the increase of hyaluronic acid. Although the detailed mecha-
nism is not elucidated, we have provided evidence for a func-
tion of GT1b as a strong inducer of the accumulation of hyal-
uronic acid and subsequent morphologic changes in orbital
fibroblasts. Hyaluronic acid is mainly a pericellular matrix com-
ponent; however, intracellular hyaluronic acid has been local-
ized in cytoplasm and the nuclei of proliferating cells.39,40
When hyaluronic acid is taken up from the pericellular matrix,
it is destined for eventual degradation in the lysosomes.41 In
our study, the increase of intracellular hyaluronic acid induced
by GT1b treatment partly co-localized with the lysosomes. In
addition, human orbit possesses no organized lymphatic net,42
into which most extracellular hyaluronic acid eventually dif-
fuses for subsequent catabolizing.43 The specific characteris-
tics of orbital fibroblasts, resident in orbit where no lymphatic
outflow system exist, may explain the abundance of hyaluronic
acid in the lysosomes of orbital fibroblasts observed in our
system. In terms of TAO, it will be interesting to determine
whether gangliosides, including GT1b, affect the expression
and activity of hyaluronidase in orbital fibroblasts.
In this study, GT1b induced the morphologic changes in
orbital fibroblasts but failed to do so in dermal ones or preadi-
pocytes. Unlike other fibroblasts derived mostly from the me-
soderm, orbital fibroblasts are known to originate from the
neuroectoderm.44 Orbital fibroblasts have unique site-specific
characteristics compared with other types of fibroblasts.1 Pro-
inflammatory cytokines, such as leukoregulin and IL-1, potenti-
ate the induction of orbital fibroblast genes that play important
roles in the orbital inflammatory responses but do not stimulate
inflammatory response in dermal fibroblasts.45,46 Such site-spe-
cific characteristics of orbital fibroblasts may be relevant to our
results. In addition, orbital fibroblasts comprise two subsets based
on the surface expression of Thy-1, a surface glycoprotein.26 Each
subset can respond to different extracellular stimuli and differen-
tiate into distinct cell types. Thy-1 fibroblasts can differentiate
into myofibroblasts when treated with TGF-ß, whereas Thy-1
ones can differentiate into mature adipocyte by peroxisome
proliferator-activated receptor  agonists as well as with c-AMP-
enhancing agents.47,48 Thy-1 is overexpressed in orbital tissues
in TAO,49 and Thy-1 cells are capable of cytokine-induced
production of prostaglandin E2, interleukin-8, and hyaluronic
acid.48 In accordance with these previous reports, our data
demonstrated that Thy-1 orbital fibroblasts increased hyal-
uronic acid by exogenous GT1b, whereas Thy-1 ones failed to
do so.
In summary, our results provide initial evidence that gan-
gliosides, especially GT1b, have a possible role in the patho-
genesis of TAO, and this suggests that further investigations are
warranted for new possible therapeutic targets against sialyl-
transferases and gangliosides. Moreover, considering that hyal-
uronidase successfully attenuated the effect of GT1b on orbital
fibroblasts, this also suggests the possibility that hyaluronidase
may be a candidate for new localized therapeutic or preventive
modality.
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